UPADACITINIB (Rinvoq®)

Clinical Indication

Moderate rheumatoid arthritis in adults

Comments

In line with NICE TA744

Implementation date 10th February 2022

Date of classification

December 2021

Review date

December 2021

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.